Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

International Journal of Nanomedicine

Volumn 13, Issue , 2018, Pages 1569-1583

  Ganesan, Palanivel ^a   Ramalingam, Prakash ^b,c   Karthivashan, Govindarajan ^a   Ko, Young Tag ^c   Choi, Dong Kug ^a  

^a Konkuk University   (South Korea)

^b UNIVERSITY OF THE SCIENCES   (United States)

^c Gachon University College of Medicine   (South Korea)

Author keywords

Chitosan; Chronic diseases; Phyto bioactive compounds; Solid lipid nanoparticles; Surface modified solid lipid nanoparticles

Indexed keywords

BIOLOGICAL PRODUCT; CAFFEIC ACID; CURCUMIN; EPIGALLOCATECHIN GALLATE; FICUS BENGALENSIS EXTRACT; HESPERIDIN; NANOPARTICLE; QUERCETIN; RESVERATROL; SOLID LIPID NANOPARTICLE; SURFACE MODIFIED SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; ZERUMBONE; DRUG CARRIER; LIPID;

ALZHEIMER DISEASE; ANTIDIABETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HEART PROTECTION; HUMAN; LIVER INJURY; MALIGNANT NEOPLASM; MOLECULAR STABILITY; NANOMEDICINE; NONHUMAN; OBESITY; PARKINSON DISEASE; PARTICLE SIZE; PHYSICAL CHEMISTRY; PHYSICAL PARAMETERS; REVIEW; RHEUMATOID ARTHRITIS; BRAIN; CHEMISTRY; DRUG EFFECT; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; BRAIN; CHRONIC DISEASE; CURCUMIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; NANOPARTICLES; PARTICLE SIZE;

EID: 85044338935     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S155593     Document Type: Review

References (198)

1. Ayan AK, Yenilmez A, Eroglu H. Evaluation of radiolabeled curcumin-loaded solid lipid nanoparticles usage as an imaging agent in liver-spleen scintigraphy. Mater Sci Eng C Mater Biol Appl. 2017;75:663–670.
2. Comoglu T, Arisoy S, Akkus ZB. Nanocarriers for effective brain drug delivery. Curr Top Med Chem. 2017;17(13):1490–1506.
3. 2. J Supercrit Fluids. 2017;120:432–442.
4. Sandri G, Motta S, Bonferoni MC, et al. Chitosan-coupled solid lipid nanoparticles: tuning nanostructure and mucoadhesion. Eur J Pharm Biopharm. 2017;110:13–18.
5. Pistollato F, Bremer-Hoffmann S, Basso G, et al. Targeting glioblastoma with the use of phytocompounds and nanoparticles. Target Oncol. 2015;11(1):1–16.
6. Pistollato F, Giampieri F, Battino M. The use of plant-derived bioactive compounds to target cancer stem cells and modulate tumor microenvironment. Food Chem Toxicol. 2015;75:58–70.
7. Ramalingam P, Ko YT. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations. Pharm Res. 2015;32(2):389–402.
8. Ramalingam P, Yoo SW, Ko YT. Nanodelivery systems based on mucoadhesive polymer coated solid lipid nanoparticles to improve the oral intake of food curcumin. Food Res Int. 2016;84:113–119.
9. Lee WH, Loo CY, Young PM, Traini D, Mason RS, Rohanizadeh R. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin Drug Deliv. 2014;11(8):1183–1201.
10. Niu Z, Conejos-Sanchez I, Griffin BT, O’Driscoll CM, Alonso MJ. Lipid-based nanocarriers for oral peptide delivery. Adv Drug Deliv Rev. 2016;106(Pt B):337–354.
11. Raja MA, Zeenat S, Arif M, Liu C. Self-assembled nanoparticles based on amphiphilic chitosan derivative and arginine for oral curcumin delivery. Int J Nanomedicine. 2016;11:4397–4412.
12. Ramalingam P, Ko YT. Improved oral delivery of resveratrol from N-trimethyl chitosan-g-palmitic acid surface-modified solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2016;139:52–61.
13. Ramalingam P, Ko YT. Validated LC-MS/MS method for simultaneous quantification of resveratrol levels in mouse plasma and brain and its application to pharmacokinetic and brain distribution studies. J Pharm Biomed Anal. 2016;119:71–75.
14. Ikeuchi-Takahashi Y, Ishihara C, Onishi H. Formulation and evaluation of morin-loaded solid lipid nanoparticles. Biol Pharm Bull. 2016;39(9):1514–1522.
15. Grandhi BK, Thakkar A, Wang J, Prabhu S. A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions. Cancer Prev Res (Phila). 2013;6(10):1015–1025.
16. Kakkar V, Mishra AK, Chuttani K, Kaur IP. Proof of concept studies to confirm the delivery of curcumin loaded solid lipid nanoparticles (C-SLNs) to brain. Int J Pharm. 2013;448(2):354–359.
17. Liu J, Chen S, Lv L, Song L, Guo S, Huang S. Recent progress in studying curcumin and its nano-preparations for cancer therapy. Curr Pharm Des. 2013;19(11):1974–1993.
18. Shome S, Talukdar AD, Choudhury MD, Bhattacharya MK, Upadhyaya H. Curcumin as potential therapeutic natural product: a nanobiotechnological perspective. J Pharm Pharmacol. 2016;68(12):1481–1500.
19. Vijayakumar A, Baskaran R, Jang YS, Oh SH, Yoo BK. Quercetin-loaded solid lipid nanoparticle dispersion with improved physicochemical properties and cellular uptake. AAPS PharmSciTech. 2017;18(3):875–883.
20. Singh N, Khullar N, Kakkar V, Kaur IP. Sesamol loaded solid lipid nanoparticles: a promising intervention for control of carbon tetrachloride induced hepatotoxicity. BMC Complement Altern Med. 2015;15:142.
21. Singh N, Khullar N, Kakkar V, Kaur IP. Hepatoprotective effects of sesamol loaded solid lipid nanoparticles in carbon tetrachloride induced sub-chronic hepatotoxicity in rats. Environ Toxicol. 2016;31(5):520–532.
22. Kakkar V, Muppu SK, Chopra K, Kaur IP. Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. Eur J Pharm Biopharm. 2013;85(3 Pt A):339–345.
23. Frozza RL, Bernardi A, Paese K, et al. Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J Biomed Nanotechnol. 2010;6(6):694–703.
24. Ahmad N, Banala VT, Kushwaha P, et al. Quercetin-loaded solid lipid nanoparticles improve osteoprotective activity in an ovariectomized rat model: a preventive strategy for post-menopausal osteoporosis. RSC Adv. 2016;6(100):97613–97628.
25. Luo CF, Yuan M, Chen MS, et al. Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration. Int J Pharm. 2011;410(1–2):138–144.
26. Aditya NP, Ko S. Solid lipid nanoparticles (SLNs): delivery vehicles for food bioactives. RSC Adv. 2015;5(39):30902–30911.
27. Aditya NP, Patankar S, Madhusudhan B, Murthy RSR, Souto EB. Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: pharmacokinetics, toxicological and in vivo anti-malarial activity. Eur J Pharm Sci. 2010;40(5):448–455.
28. Aditya NP, Aditya S, Yang H, Kim HW, Park SO, Ko S. Co-delivery of hydrophobic curcumin and hydrophilic catechin by a water-in-oil-in-water double emulsion. Food Chem. 2015;173:7–13.
29. Aditya NP, Shim M, Yang H, Lee Y, Ko S. Antiangiogenic effect of combined treatment with curcumin and genistein on human prostate cancer cell line. J Funct Foods. 2014;8:204–213.
30. Choi KO, Aditya NP, Ko S. Effect of aqueous pH and electrolyte concentration on structure, stability and flow behavior of non-ionic surfactant based solid lipid nanoparticles. Food Chem. 2014;147:239–244.
31. Aditya NP, Aditya S, Yang HJ, et al. Curcumin and catechin co-loaded water-in-oil-in-water emulsion and its beverage application. J Funct Foods. 2015;15:35–43.
32. Aditya NP, Macedo AS, Doktorovov S, et al. Development and evaluation of lipid nanocarriers for quercetin delivery: a comparative study of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoemulsions (LNE). LWT Food Sci Technol. 2014;59(1):115–121.
33. Ji P, Yu T, Liu Y, et al. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics. Drug Des Devel Ther. 2016;10:911–925.
34. Kumar P, Sharma G, Kumar R, et al. Vitamin-derived nanolipoidal carriers for brain delivery of dimethyl fumarate: a novel approach with preclinical evidence. ACS Chem Neurosci. 2017;8(6):1390–1396.
35. Lingling G, Yuan Z, Weigen L. Preparation, optimization, characterization and in vivo pharmacokinetic study of asiatic acid tromethamine salt-loaded solid lipid nanoparticles. Drug Dev Ind Pharm. 2016;42(8):1325–1333.
36. Madureira AR, Campos D, Gullon B, et al. Fermentation of bioactive solid lipid nanoparticles by human gut microflora. Food Funct. 2016;7(1):516–529.
37. Neves AR, Martins S, Segundo MA, Reis S. Nanoscale delivery of resveratrol towards enhancement of supplements and nutraceuticals. Nutrients. 2016;8(3):131.
38. Siafaka PI, Ustundag Okur N, Karavas E, Bikiaris DN. Surface modified multifunctional and stimuli responsive nanoparticles for drug targeting: current status and uses. Int J Mol Sci. 2016;17(9).
39. Tan ME, He CH, Jiang W, et al. Development of solid lipid nanoparticles containing total flavonoid extract from Dracocephalum moldavica L. and their therapeutic effect against myocardial ischemia-reperfusion injury in rats. Int J Nanomedicine. 2017;12:3253–3265.
40. Wang T, Ma X, Lei Y, Luo Y. Solid lipid nanoparticles coated with cross-linked polymeric double layer for oral delivery of curcumin. Colloids Surf B Biointerfaces. 2016;148:1–11.
41. Dening TJ, Rao S, Thomas N, Prestidge CA. Oral nanomedicine approaches for the treatment of psychiatric illnesses. J Control Release. 2016;223:137–156.
42. Ma Y, He H, Xia F, et al. In vivo fate of lipid-silybin conjugate nanoparticles: implications on enhanced oral bioavailability. Nanomedicine. 2017;13(6):2643–2654.
43. Nunes S, Madureira AR, Campos D, et al. Solid lipid nanoparticles as oral delivery systems of phenolic compounds: overcoming pharmacokinetic limitations for nutraceutical applications. Crit Rev Food Sci Nutr. 2017;57(9):1863–1873.
44. Anand K, Tiloke C, Naidoo P, Chuturgoon AA. Phytonanotherapy for management of diabetes using green synthesis nanoparticles. J Photochem Photobiol B. 2017;173:626–639.
45. Bulle S, Reddyvari H, Nallanchakravarthula V, Vaddi DR. Therapeutic potential of Pterocarpus santalinus L.: an update. Pharmacogn Rev. 2016;10(19):43–49.
46. Chen CY, Chiu FY, Lin Y, Huang WJ, Hsieh PS, Hsu FL. Chemical constituents analysis and antidiabetic activity validation of four fern species from Taiwan. Int J Mol Sci. 2015;16(2):2497–2516.
47. Dey P, Saha MR, Chowdhuri SR, et al. Assessment of anti-diabetic activity of an ethnopharmacological plant Nerium oleander through alloxan induced diabetes in mice. J Ethnopharmacol. 2015;161:128–137.
48. Singh AK, Jatwa R, Purohit A, Ram H. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes. J Asian Nat Prod Res. 2017;19(10):1036–1045.
49. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012;35(11):2121–2127.
50. Movahed A, Nabipour I, Lieben Louis X, et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med. 2013;2013:851267.
51. Xue M, Yang MX, Zhang W, et al. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Int J Nanomedicine. 2013;8:4677–4687.
52. Xue M, Zhang L, Yang MX, et al. Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice. Int J Nanomedicine. 2015;10:5049–5057.
53. Chen SS, Michael A, Butler-Manuel SA. Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals. Discov Med. 2012;13(68):7–17.
54. Mahata S, Maru S, Shukla S, et al. Anticancer property of Bryophyllum pinnata (Lam.) Oken. leaf on human cervical cancer cells. BMC Complement Altern Med. 2012;12:15.
55. Nie Q, Xing M, Hu J, Hu X, Nie S, Xie M. Metabolism and health effects of phyto-estrogens. Crit Rev Food Sci Nutr. 2017;57(11):2432–2454.
56. Rani N, Velan LP, Vijaykumar S, Arunachalam A. An insight into the potentially old-wonder molecule-quercetin: the perspectives in foresee. Chin J Integr Med. Epub 2015 Sep 9.
57. Davatgaran-Taghipour Y, Masoomzadeh S, Farzaei MH, et al. Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective. Int J Nanomedicine. 2017;12:2689–2702.
58. Park JS, Ahn EY, Park Y. Asymmetric dumbbell-shaped silver nanoparticles and spherical gold nanoparticles green-synthesized by mangosteen (Garcinia mangostana) pericarp waste extracts. Int J Nanomedicine. 2017;12:6895–6908.
59. Hazzah HA, Farid RM, Nasra MM, et al. A new approach for treatment of precancerous lesions with curcumin solid-lipid nanoparticle-loaded gels: in vitro and clinical evaluation. Drug Deliv. 2016;23(4):1409–1419.
60. Li C, Zhang J, Zu YJ, et al. Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of phytochemicals. Chin J Nat Med. 2015;13(9):641–652.
61. Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014;35(10):3365–3383.
62. Sun J, Bi C, Chan HM, Sun S, Zhang Q, Zheng Y. Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability. Colloids Surf B Biointerfaces. 2013;111:367–375.
63. Kim JT, Barua S, Kim H, et al. Absorption study of genistein using solid lipid microparticles and nanoparticles: control of oral bioavailability by particle sizes. Biomol Ther (Seoul). 2017;25(4):452–459.
64. Wang L, Li H, Wang S, et al. Enhancing the antitumor activity of berberine hydrochloride by solid lipid nanoparticle encapsulation. AAPS PharmSciTech. 2014;15(4):834–844.
65. Chen R, Wang S, Zhang J, Chen M, Wang Y. Aloe-emodin loaded solid lipid nanoparticles: formulation design and in vitro anti-cancer study. Drug Deliv. 2014;22(5):666–674.
66. Zhang QH, Xiong QP, Shi YY, Zhang DY. [Study on preparation and characterization of resveratrol solid lipid nanoparticles and its anticancer effects in vitro]. Zhong Yao Cai. 2010;33(12):1929–1932. Chinese [with English abstract].
67. Wang L, Wang S, Chen R, et al. Oridonin loaded solid lipid nanoparticles enhanced antitumor activity in MCF-7 cells. J Nanomater. 2014;2014:903646.
68. Jin Q, Yu H, Li P. The evaluation and utilization of marine-derived bioactive compounds with anti-obesity effect. Curr Med Chem. Epub 2017 Jun 1.
69. Pan MH, Tung YC, Yang G, Li S, Ho CT. Molecular mechanisms of the anti-obesity effect of bioactive compounds in tea and coffee. Food Funct. 2016;7(11):4481–4491.
70. Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises? Int J Mol Sci. 2011;12(9):5592–5603.
71. Frias I, Neves AR, Pinheiro M, Reis S. Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation. Drug Des Devel Ther. 2016;10:3519–3528.
72. Hemn HO, Noordin MM, Rahman HS, Hazilawati H, Zuki A, Chartrand MS. Antihypercholesterolemic and antioxidant efficacies of zerumbone on the formation, development, and establishment of atherosclerosis in cholesterol-fed rabbits. Drug Des Devel Ther. 2015;9:4173–4208.
73. Chang CC, Lin KY, Peng KY, Day YJ, Hung LM. Resveratrol exerts anti-obesity effects in high-fat diet obese mice and displays differential dosage effects on cytotoxicity, differentiation, and lipolysis in 3T3-L1 cells. Endocr J. 2016;63(2):169–178.
74. Vijayakumar A, Baskaran R, Jang YS, Oh SH, Yoo BK. Quercetin-loaded solid lipid nanoparticle dispersion with improved physicochemical properties and cellular uptake. AAPS PharmSciTech. 2016;18(3):875–883.
75. Olas B. Sea buckthorn as a source of important bioactive compounds in cardiovascular diseases. Food Chem Toxicol. 2016;97:199–204.
76. Rangel-Huerta OD, Pastor-Villaescusa B, Aguilera CM, Gil A. A systematic review of the efficacy of bioactive compounds in cardiovascular disease: phenolic compounds. Nutrients. 2015;7(7):5177–5216.
77. Sola R, Valls RM, Puzo J, et al. Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial. PLoS One. 2014;9(8):e101978.
78. Malaguti M, Angeloni C, Hrelia S. Nutraceutical bioactive compounds promote healthspan counteracting cardiovascular diseases. J Am Coll Nutr. 2015;34 Suppl 1:22–27.
79. Pastor-Villaescusa B, Rangel-Huerta OD, Aguilera CM, Gil A. A systematic review of the efficacy of bioactive compounds in cardiovascular disease: carbohydrates, active lipids and nitrogen compounds. Ann Nutr Metab. 2015;66(2–3):168–181.
80. Scolaro B, Soo Jin Kim H, de Castro IA. Bioactive compounds as an alternative for drug co-therapy: overcoming challenges in cardiovascular disease prevention. Crit Rev Food Sci Nutr. Epub 2016 Nov 10:1–14.
81. Luo CF, Chen MS, Professor Y, et al. Metabolic profile of puerarin in rats after intragastric administration of puerarin solid lipid nanoparticles. Int J Nanomedicine. 2013;8:933–940.
82. Ezhilarasi PN, Muthukumar SP, Anandharamakrishnan C. Solid lipid nanoparticle enhances bioavailability of hydroxycitric acid compared to a microparticle delivery system. RSC Adv. 2016;6(59):53784–53793.
83. Gupta SC, Tyagi AK, Deshmukh-Taskar P, Hinojosa M, Prasad S, Aggarwal BB. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Arch Biochem Biophys. 2014;559:91–99.
84. Khalife S, Zafarullah M. Molecular targets of natural health products in arthritis. Arthritis Res Ther. 2011;13(1):102.
85. Rahman M, Beg S, Verma A, et al. Phytoconstituents as pharmacotherapeutics in rheumatoid arthritis: challenges and scope of nano/submicromedicine in its effective delivery. J Pharm Pharmacol. 2017;69(1):1–14.
86. Mobasheri A, Henrotin Y, Biesalski HK, Shakibaei M. Scientific evidence and rationale for the development of curcumin and resveratrol as nutraceutricals for joint health. Int J Mol Sci. 2012;13(4):4202–4232.
87. Recio MC, Andujar I, Rios JL. Anti-inflammatory agents from plants: progress and potential. Curr Med Chem. 2012;19(14):2088–2103.
88. Shakibaei M, Mobasheri A, Buhrmann C. Curcumin synergizes with resveratrol to stimulate the MAPK signaling pathway in human articular chondrocytes in vitro. Genes Nutr. 2011;6(2):171–179.
89. Bhalekar MR, Madgulkar AR, Desale PS, Marium G. Formulation of piperine solid lipid nanoparticles (SLN) for treatment of rheumatoid arthritis. Drug Dev Ind Pharm. 2017;43(6):1003–1010.
90. Arora R, Kuhad A, Kaur IP, Chopra K. Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats. Eur J Pain. 2015;19(7):940–952.
91. Chen J, Wei N, Lopez-Garcia M, et al. Development and evaluation of resveratrol, Vitamin E, and epigallocatechin gallate loaded lipid nanoparticles for skin care applications. Eur J Pharm Biopharm. 2017;117:286–291.
92. Fonseca-Santos B, Gremiao MP, Chorilli M. Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine. 2015;10:4981–5003.
93. Loureiro JA, Andrade S, Duarte A, et al. Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer’s disease. Molecules. 2017;22(2).
94. Picone P, Bondi ML, Montana G, et al. Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: improved delivery by solid lipid nanoparticles. Free Radic Res. 2009;43(11):1133–1145.
95. Sachdeva AK, Misra S, Pal Kaur I, Chopra K. Neuroprotective potential of sesamol and its loaded solid lipid nanoparticles in ICV-STZ-induced cognitive deficits: behavioral and biochemical evidence. Eur J Pharmacol. 2015;747:132–140.
96. Yusuf M, Khan M, Khan RA, Ahmed B. Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease model. J Drug Target. 2012;21(3):300–311.
97. Barbu E, Molnar E, Tsibouklis J, Gorecki DC. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin Drug Deliv. 2009;6(6):553–565.
98. Filipova M, Rusina R, Holada K. Nanoparticle-based drug delivery systems crossing blood-brain barrier hope for future treatment of neurodegenerative disorders? Cesk Slov Neurol N. 2016;79(2):160–167.
99. Shah B, Khunt D, Bhatt H, Misra M, Padh H. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur J Pharm Sci. 2015;78:54–66.
100. Wilson CM, Magnaudeix A, Naves T, Vincent F, Lalloue F, Jauberteau MO. The ins and outs of nanoparticle technology in neurodegenerative diseases and cancer. Curr Drug Metab. 2015;16(8):609–632.
101. Zhang GL, Chen LK, Guo XY, Khan AA, Gu YC, Gu N. Nanoparticle-mediated drug delivery systems (DDS) in the central nervous system. Curr Org Chem. 2017;21(3):272–283.
102. Dhawan S, Kapil R, Singh B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol. 2011;63(3):342–351.
103. Bondi ML, Montana G, Craparo EF, et al. Ferulic acid-loaded lipid nanostructures as drug delivery systems for Alzheimer’s disease: preparation, characterization and cytotoxicity studies. Curr Nanosci. 2009;5(1):26–32.
104. Barbara R, Belletti D, Pederzoli F, et al. Novel curcumin loaded nanoparticles engineered for blood-brain barrier crossing and able to disrupt Abeta aggregates. Int J Pharm. 2017;526(1–2):413–424.
105. Battisti A, Piccionello AP, Sgarbossa A, et al. Curcumin-like compounds designed to modify amyloid beta peptide aggregation patterns. RSC Adv. 2017;7(50):31714–31724.
106. Chandra B, Mithu VS, Bhowmik D, et al. Curcumin dictates divergent fates for the central salt bridges in amyloid-β40 and amyloid-β42. Biophys J. 2017;112(8):1597–1608.
107. Di Martino P, Censi R, Gigliobianco MR, et al. Nano-medicine improving the bioavailability of small molecules for the prevention of neurodegenerative diseases. Curr Pharm Des. 2017;23(13):1897–1908.
108. Jaroonwitchawan T, Chaicharoenaudomrung N, Natnkaew J, Noisa P. Curcumin attenuates paraquat-induced cell death in human neuroblastoma cells through modulating oxidative stress and autophagy. Neurosci Lett. 2017;636:40–47.
109. Karimian MS, Pirro M, Johnston TP, Majeed M, Sahebkar A. Curcumin and endothelial function: evidence and mechanisms of protective effects. Curr Pharm Des. 2017;23(17):2462–2473.
110. McClure R, Ong H, Janve V, et al. Aerosol delivery of curcumin reduced amyloid-β deposition and improved cognitive performance in a transgenic model of Alzheimer’s disease. J Alzheimers Dis. 2017;55(2):797–811.
111. Ullah F, Liang A, Rangel A, Gyengesi E, Niedermayer G, Munch G. High bioavailability curcumin: an anti-inflammatory and neurosupportive bioactive nutrient for neurodegenerative diseases characterized by chronic neuroinflammation. Arch Toxicol. 2017;91(4):1623–1634.
112. Zeng Z, Shen ZL, Zhai S, et al. Transport of curcumin derivatives in Caco-2 cell monolayers. Eur J Pharm Biopharm. 2017;117:123–131.
113. Kakkar V, Kaur IP. Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food Chem Toxicol. 2011;49(11):2906–2913.
114. Ahmed T, Javed S, Javed S, et al. Resveratrol and Alzheimer’s disease: mechanistic insights. Mol Neurobiol. 2017;54(4):2622–2635.
115. Cheng J, Rui Y, Qin L, et al. Vitamin D combined with resveratrol prevents cognitive decline in SAMP8 mice. Curr Alzheimer Res. 2017;14(8):820–833.
116. Famenini S, Rigali EA, Olivera-Perez HM, et al. Increased intermediate M1–M2 macrophage polarization and improved cognition in mild cognitive impairment patients on omega-3 supplementation. FASEB J. 2017;31(1):148–160.
117. He X, Li Z, Rizak JD, et al. Resveratrol attenuates formaldehyde induced hyperphosphorylation of Tau protein and cytotoxicity in N2a cells. Front Neurosci. 2016;10:598.
118. Jerabek J, Uliassi E, Guidotti L, et al. Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer’s disease. Eur J Med Chem. 2017;127:250–262.
119. Moussa C, Hebron M, Huang X, et al. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J Neuroinflammation. 2017;14(1):1.
120. Noratiqah SB, Naina-Mohamed I, Zulfarina MS, Qodriyah HM. Natural polyphenols in the treatment of Alzheimer’s disease. Curr Drug Targets. Epub 2017 Mar 28.
121. Omar SH, Scott CJ, Hamlin AS, Obied HK. The protective role of plant biophenols in mechanisms of Alzheimer’s disease. J Nutr Biochem. 2017;47:1–20.
122. Wightman EL. Potential benefits of phytochemicals against Alzheimer’s disease. Proc Nutr Soc. 2017;76(2):106–112.
123. Xu P, Zhang M, Sheng R, Ma Y. Synthesis and biological evaluation of deferiprone-resveratrol hybrids as antioxidants, Abeta1-42 aggregation inhibitors and metal-chelating agents for Alzheimer’s disease. Eur J Med Chem. 2017;127:174–186.
124. Cury RG, Fraix V, Castrioto A, et al. Thalamic deep brain stimulation for tremor in Parkinson disease, essential tremor, and dystonia. Neurology. 2017;89(13):1416–1423.
125. Kanegusuku H, Silva-Batista C, Pecanha T, et al. Patients with Parkinson disease present high ambulatory blood pressure variability. Clin Physiol Funct Imaging. 2017;37(5):530–535.
126. Park J, Lee JW, Cooper SC, Broxmeyer HE, Cannon JR, Kim CH. Parkinson disease-associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response. J Leukoc Biol. 2017;102(4):1093–1102.
127. Ramirez AI, de Hoz R, Salobrar-Garcia E, et al. The role of microglia in retinal neurodegeneration: Alzheimer’s disease, Parkinson, and glaucoma. Front Aging Neurosci. 2017;9:214.
128. Saez-Atienzar S, Singleton AB. Parkinson disease and clathrin coat dynamics at synapses, why not? Mov Disord. 2017;32(8):1163.
129. Son HJ, Jeong YJ, Yoon HJ, et al. Parkinson disease-related cortical and striatal cognitive patterns in dual time F-18 FP CIT: evidence for neural correlates between the caudate and the frontal lobe. Q J Nucl Med Mol Imaging. Epub 2017 Jul 27.
130. Strupp J, Kunde A, Galushko M, Voltz R, Golla H. Severely affected by Parkinson disease: the patient’s view and implications for palliative care. Am J Hosp Palliat Care. Epub 2017 Jan 1.
131. da Costa IM, Cavalcanti JRLP, de Queiroz DB, et al. Supplementation with herbal extracts to promote behavioral and neuroprotective effects in experimental models of Parkinson’s disease: a systematic review. Phytother Res. 2017;31(7):959–970.
132. Ganesan P, Ko HM, Kim IS, Choi DK. Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson’s disease models. Int J Nanomedicine. 2015;10:6757–6772.
133. Gokul K, Muralidhara. Oral supplements of aqueous extract of tomato seeds alleviate motor abnormality, oxidative impairments and neurotoxicity induced by rotenone in mice: relevance to Parkinson’s disease. Neurochem Res. 2014;39(7):1382–1394.
134. Guo H, Shi F, Li M, Liu Q, Yu B, Hu L. Neuroprotective effects of Eucommia ulmoides Oliv. and its bioactive constituent work via ameliorating the ubiquitin-proteasome system. BMC Complement Altern Med. 2015;15:151.
135. Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1–222.
136. Mazo NA, Echeverria V, Cabezas R, et al. Medicinal plants as protective strategies against Parkinson’s disease. Curr Pharm Des. 2017;23(28):4180–4188.
137. Morshedi D, Aliakbari F, Tayaranian-Marvian A, Fassihi A, Pan-Montojo F, Pérez-Sánchez H. Cuminaldehyde as the major component of Cuminum cyminum, a natural aldehyde with inhibitory effect on alpha-synuclein fibrillation and cytotoxicity. J Food Sci. 2015;80(10):H2336–H2345.
138. Mythri RB, Harish G, Bharath MM. Therapeutic potential of natural products in Parkinson’s disease. Recent Pat Endocr Metab Immune Drug Discov. 2012;6(3):181–200.
139. Nabavi SF, Braidy N, Habtemariam S, Sureda A, Manayi A, Nabavi SM. Neuroprotective effects of fisetin in Alzheimer’s and Parkinson’s diseases: from chemistry to medicine. Curr Top Med Chem. 2016;16(17):1910–1915.
140. Pathak A, Srivastava AK, Singour PK, Gouda P. Synthetic and natural monoamine oxidase inhibitors as potential lead compounds for effective therapeutics. Cent Nerv Syst Agents Med Chem. 2016;16(2):81–97.
141. Solanki I, Parihar P, Mansuri ML, Parihar MS. Flavonoid-based therapies in the early management of neurodegenerative diseases. Adv Nutr. 2015;6(1):64–72.
142. Cacciatore I, Ciulla M, Fornasari E, Marinelli L, Di Stefano A. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opin Drug Deliv. 2016;13(8):1121–1131.
143. Cunha S, Amaral MH, Lobo JM, Silva AC. Therapeutic strategies for Alzheimer’s and Parkinson’s diseases by means of drug delivery systems. Curr Med Chem. 2016;23(31):3618–3631.
144. Chen T, Deng Y, Liao X, et al. [Effect of curcumin on oligomer formation and mitochondrial ATP-sensitive potassium channels induced by overexpression or mutation of α-synuclein]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2015;32(4):462–467. Chinese [with English abstract].
145. Cui Q, Li X, Zhu H. Curcumin ameliorates dopaminergic neuronal oxidative damage via activation of the Akt/Nrf2 pathway. Mol Med Rep. 2016;13(2):1381–1388.
146. Du XX, Xu HM, Jiang H, Song N, Wang J, Xie JX. Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson’s disease. Neurosci Bull. 2012;28(3):253–258.
147. Guerrero-Muñoz MJ, Castillo-Carranza DL, Kayed R. Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochem Pharmacol. 2014;88(4):468–478.
148. Phom L, Achumi B, Alone DP, Muralidhara, Yenisetti SC. Curcumin’s neuroprotective efficacy in Drosophila model of idiopathic Parkinson’s disease is phase specific: implication of its therapeutic effectiveness. Rejuvenation Res. 2014;17(6):481–489.
149. Song S, Nie Q, Li Z, Du G. Curcumin improves neurofunctions of 6-OHDA-induced parkinsonian rats. Pathol Res Pract. 2016;212(4):247–251.
150. Spinelli KJ, Osterberg VR, Meshul CK, Soumyanath A, Unni VK. Curcumin treatment improves motor behavior in α-synuclein transgenic mice. PLoS One. 2015;10(6):e0128510.
151. Uğuz AC, Öz A, Naziroğlu M. Curcumin inhibits apoptosis by regulating intracellular calcium release, reactive oxygen species and mitochondrial depolarization levels in SH-SY5Y neuronal cells. J Recept Signal Transduct Res. 2016;36(4):395–401.
152. Yu SY, Zhang M, Luo J, Zhang L, Shao Y, Li G. Curcumin ameliorates memory deficits via neuronal nitric oxide synthase in aged mice. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:47–53.
153. Abdel-Wahab WM. Thymoquinone attenuates toxicity and oxidative stress induced by bisphenol A in liver of male rats. Pak J Biol Sci. 2014;17(11):1152–1160.
154. Babu PR, Bhuvaneswar C, Sandeep G, Ramaiah CV, Rajendra W. Hepatoprotective role of Ricinus communis leaf extract against d-galactosamine induced acute hepatitis in albino rats. Biomed Pharmacother. 2017;88:658–666.
155. Dongiovanni P, Lanti C, Riso P, Valenti L. Nutritional therapy for nonalcoholic fatty liver disease. J Nutr Biochem. 2016;29:1–11.
156. El-Hadary AE, Ramadan Hassanien MF. Hepatoprotective effect of cold-pressed Syzygium aromaticum oil against carbon tetrachloride (CCl4)-induced hepatotoxicity in rats. Pharm Biol. 2016;54(8):1364–1372.
157. Fu YQ, Hua C, Zhou J, Cheng BR, Zhang J. Protective effects of ginseng total saponins against hepatic ischemia/reperfusion injury in experimental obstructive jaundice rats. Pharm Biol. 2013;51(12):1545–1551.
158. Huang HP, Ou TT, Wang CJ. Mulberry (sang shen zi) and its bioactive compounds, the chemoprevention effects and molecular mechanisms in vitro and in vivo. J Tradit Complement Med. 2013;3(1):7–15.
159. Inada AC, Figueiredo PS, Santos-Eichler RAD, et al. Morinda citrifolia Linn. (Noni) and its potential in obesity-related metabolic dysfunction. Nutrients. 2017;9(6).
160. Kowalska K, Olejnik A. Current evidence on the health-beneficial effects of berry fruits in the prevention and treatment of metabolic syndrome. Curr Opin Clin Nutr Metab Care. 2016;19(6):446–452.
161. Mopuri R, Islam MS. Medicinal plants and phytochemicals with anti-obesogenic potentials: a review. Biomed Pharmacother. 2017;89:1442–1452.
162. Rodriguez-Ramiro I, Vauzour D, Minihane AM. Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms. Proc Nutr Soc. 2016;75(1):47–60.
163. Samout N, Ettaya A, Bouzenna H, Ncib S, Elfeki A, Hfaiedh N. Beneficial effects of Plantago albicans on high-fat diet-induced obesity in rats. Biomed Pharmacother. 2016;84:1768–1775.
164. Valenti L, Riso P, Mazzocchi A, Porrini M, Fargion S, Agostoni C. Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2013;2013:145421.
165. Xu WH, Hu HG, Tian Y, et al. Bioactive compound reveals a novel function for ribosomal protein S5 in hepatic stellate cell activation and hepatic fibrosis. Hepatology. 2014;60(2):648–660.
166. Yu JY, Ha JY, Kim KM, Jung YS, Jung JC, Oh S. Anti-inflammatory activities of licorice extract and its active compounds, glycyrrhizic acid, liquiritin and liquiritigenin, in BV2 cells and mice liver. Molecules. 2015;20(7):13041–13054.
167. Abdelwahab SI, Sheikh BY, Taha MM, et al. Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. Int J Nanomedicine. 2013;8:2163–2172.
168. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305–313.
169. Rao MP, Manjunath K, Bhagawati ST, Thippeswamy BS. Bixin loaded solid lipid nanoparticles for enhanced hepatoprotection preparation, characterisation and in vivo evaluation. Int J Pharm. 2014;473(1–2):485–492.
170. Shuhendler AJ, Prasad P, Leung M, Rauth AM, Dacosta RS, Wu XY. A novel solid lipid nanoparticle formulation for active targeting to tumor α(v) β(3) integrin receptors reveals cyclic RGD as a double-edged sword. Adv Healthc Mater. 2012;1(5):600–608.
171. Sharma AK, Kumar A, Kumar S, et al. Preparation and therapeutic evolution of Ficus benjamina solid lipid nanoparticles against alcohol abuse/antabuse induced hepatotoxicity and cardio-renal injury. RSC Adv. 2017;7(57):35938–35949.
172. Kakkar V, Mishra AK, Chuttani K, Chopra K, Kaur IP. Delivery of sesamol-loaded solid lipid nanoparticles to the brain for menopause-related emotional and cognitive central nervous system derangements. Rejuvenation Res. 2011;14(6):597–604.
173. Elzoghby AO, Abd-Elwakil MM, Abd-Elsalam K, Elsayed MT, Hashem Y, Mohamed O. Natural polymeric nanoparticles for brain-targeting: implications on drug and gene delivery. Curr Pharm Des. 2016;22(22):3305–3323.
174. Fonte P, Andrade F, Araújo F, Andrade C, Neves JD, Sarmento B. Chitosan-coated solid lipid nanoparticles for insulin delivery. Methods Enzymol. 2012;508:295–314.
175. Luo Y, Teng Z, Li Y, Wang Q. Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake. Carbohyd Polym. 2015;122:221–229.
176. Baek JS, Cho CW. Surface modification of solid lipid nanoparticles for oral delivery of curcumin: improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake. Eur J Pharm Biopharm. 2017;117:132–140.
177. Campos J, Varas-Godoy M, Haidar ZS. Physicochemical characterization of chitosan-hyaluronan-coated solid lipid nanoparticles for the targeted delivery of paclitaxel: a proof-of-concept study in breast cancer cells. Nanomedicine (Lond). 2017;12(5):473–490.
178. Nguyen HM, Hwang IC, Park JW, Park HJ. Photoprotection for deltamethrin using chitosan-coated beeswax solid lipid nanoparticles. Pest Manag Sci. 2012;68(7):1062–1068.
179. Rassu G, Soddu E, Posadino AM, et al. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy. Colloids Surf B Biointerfaces. 2017;152:296–301.
180. Wang JY, Wang Y, Meng X. Chitosan nanolayered cisplatin-loaded lipid nanoparticles for enhanced anticancer efficacy in cervical cancer. Nanoscale Res Lett. 2016;11(1):524.
181. Thakkar A, Chenreddy S, Wang J, Prabhu S. Ferulic acid combined with aspirin demonstrates chemopreventive potential towards pancreatic cancer when delivered using chitosan-coated solid-lipid nanoparticles. Cell Biosci. 2015;5:46.
182. Thakkar A, Chenreddy S, Thio A, Khamas W, Wang J, Prabhu S. Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice. Int J Nanomedicine. 2016;11:3265–3276.
183. Fathi M, Mirlohi M, Varshosaz J, Madani G. Novel caffeic acid nanocarrier: production, characterization, and release modeling. J Nanomater. 2013;2013:434632.
184. Chen F, Zhang ZR, Yuan F, Qin X, Wang M, Huang Y. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. Int J Pharm. 2008;349(1–2):226–233.
185. Han L, Tang C, Yin C. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy. Biomaterials. 2014;35(15):4589–4600.
186. Zhang J, Tang C, Yin C. Galactosylated trimethyl chitosan-cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages. Biomaterials. 2013;34(14):3667–3677.
187. Shi LL, Lu J, Cao Y, et al. Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel. Drug Dev Ind Pharm. 2017;43(5):839–846.
188. Cai J, Dang Q, Liu C, et al. Preparation, characterization and antibacterial activity of O-acetyl-chitosan-N-2-hydroxypropyl trimethyl ammonium chloride. Int J Biol Macromol. 2015;80:8–15.
189. Li GF, Wang JC, Feng XM, Liu ZD, Jiang CY, Yang JD. Preparation and testing of quaternized chitosan nanoparticles as gene delivery vehicles. Appl Biochem Biotechnol. 2015;175(7):3244–3257.
190. Xiao B, Ma P, Ma L, et al. Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages. J Colloid Interface Sci. 2017;490:520–528.
191. Yang Z, Shang Y, Huang X, et al. Cationic content effects of biodegradable amphoteric chitosan-based flocculants on the flocculation properties. J Environ Sci (China). 2012;24(8):1378–1385.
192. Zhao K, Sun Y, Chen G, et al. Biological evaluation of N-2-hydroxypropyl trimethyl ammonium chloride chitosan as a carrier for the delivery of live Newcastle disease vaccine. Carbohydr Polym. 2016;149:28–39.
193. Shi LL, Xie H, Lu J, et al. Positively charged surface-modified solid lipid nanoparticles promote the intestinal transport of docetaxel through multifunctional mechanisms in rats. Mol Pharm. 2016;13(8):2667–2676.
194. Rezzani R, Rodella LF, Fraschini F, et al. Melatonin delivery in solid lipid nanoparticles: prevention of cyclosporine A induced cardiac damage. J Pineal Res. 2009;46(3):255–261.
195. Karthivashan G, Ganesan P, Park S, Kim J, Choi D. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease. Drug delivery. 2018;25(1):307–320.
196. Sayin B, Somavarapu S, Li XW, Sesardic D, Senel S, Alpar OH. TMC–MCC (N-trimethyl chitosan–mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. Eur J Pharm Sci. 2009;38(4):362–369.
197. Yin L, Ding J, He C, Cui L, Tang C, Yin C. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials. 2009;30(29):5691–5700.
198. Slütter B, Soema PC, Ding Z, Verheul R, Hennink W, Jiskoot W. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. J Control Release. 2010;143(2):207–214.